Hansa Biopharma Yönetim

Yönetim kriter kontrolleri 2/4

Hansa Biopharma CEO'su Søren Tulstrup, Mar2018 tarihinde atandı, in görev süresi 5.83 yıldır. in toplam yıllık tazminatı SEK 26.48M olup, şirket hissesi ve opsiyonları dahil olmak üzere 28.6% maaş ve 71.4% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.06% ine doğrudan sahiptir ve bu hisseler SEK 1.03M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 4.3 yıl ve 4.7 yıldır.

Anahtar bilgiler

Søren Tulstrup

İcra Kurulu Başkanı

SEK 26.5m

Toplam tazminat

CEO maaş yüzdesi	28.6%
CEO görev süresi	5.8yrs
CEO sahipliği	0.06%
Yönetim ortalama görev süresi	4.3yrs
Yönetim Kurulu ortalama görev süresi	4.7yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Søren Tulstrup'un ücretlendirmesi Hansa Biopharma'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2023	n/a	n/a	-SEK 856m
Jun 30 2023	n/a	n/a	-SEK 759m
Mar 31 2023	n/a	n/a	-SEK 678m
Dec 31 2022	SEK 26m	SEK 8m	-SEK 611m
Sep 30 2022	n/a	n/a	-SEK 626m
Jun 30 2022	n/a	n/a	-SEK 620m
Mar 31 2022	n/a	n/a	-SEK 583m
Dec 31 2021	SEK 26m	SEK 7m	-SEK 548m
Sep 30 2021	n/a	n/a	-SEK 491m
Jun 30 2021	n/a	n/a	-SEK 465m
Mar 31 2021	n/a	n/a	-SEK 431m
Dec 31 2020	SEK 21m	SEK 6m	-SEK 421m
Sep 30 2020	n/a	n/a	-SEK 426m
Jun 30 2020	n/a	n/a	-SEK 398m
Mar 31 2020	n/a	n/a	-SEK 381m
Dec 31 2019	SEK 11m	SEK 5m	-SEK 360m
Sep 30 2019	n/a	n/a	-SEK 330m
Jun 30 2019	n/a	n/a	-SEK 298m
Mar 31 2019	n/a	n/a	-SEK 274m
Dec 31 2018	SEK 8m	SEK 4m	-SEK 248m

Tazminat ve Piyasa: Søren 'nin toplam tazminatı ($USD 2.59M ), UK pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 739.28K ).

Tazminat ve Kazançlar: Søren şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

Søren Tulstrup (58 yo)

5.8yrs

Görev süresi

SEK 26,481,000

Tazminat

Mr. Søren Tulstrup, M.Sc, has been President and Chief Executive Officer of Hansa Biopharma AB (publ) (formerly known as Hansa Medical AB (publ)) since March 20, 2018. Mr. Tulstrup served as the Chief Exec...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Søren Tulstrup	President & CEO	5.8yrs	SEK 26.48m	0.060% SEK 1.0m
Donato Spota	CFO & Senior VP	4.7yrs	Veri yok	0.011% SEK 186.1k
Christian Kjellman	Senior VP & COO	4yrs	Veri yok	0.012% SEK 203.8k
Hitto Kaufmann	Chief Scientific Officer	less than a year	Veri yok	Veri yok
Eva-Maria Joed	Vice President of Finance & Administration	4.7yrs	Veri yok	Veri yok
Klaus Sindahl	VP & Head of Investor Relations	no data	Veri yok	Veri yok
Anne Lanner	Senior VP & Chief Human Resources Officer	5yrs	Veri yok	Veri yok
Emanuel Björne	VP & Head of Business Development	no data	Veri yok	Veri yok
Lena Winstedt	Head of Science	no data	Veri yok	Veri yok
Vincenza Nigro	VP & Head of Medical Affairs	no data	Veri yok	Veri yok
Achim Kaufhold	Senior VP & Chief Medical Officer	3.6yrs	Veri yok	Veri yok
Magnus Korsgren	VP & Head of Research and Development	2.8yrs	Veri yok	Veri yok

4.3yrs

Ortalama Görev Süresi

54yo

Ortalama Yaş

Deneyimli Yönetim: HNSAS 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 4.3 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Anders Pedersen	Independent Director	5.7yrs	SEK 386.00k	0.0048% SEK 82.1k
Mats Blom	Independent Director	4.7yrs	SEK 493.00k	0.0019% SEK 32.9k
Peter Nicklin	Independent Chairman of the Board	1.6yrs	SEK 525.00k	0.028% SEK 475.6k
Eva Nilsagard	Independent Director	4.7yrs	SEK 591.00k	0.0057% SEK 98.4k
Hilary Malone	Independent Director	2.7yrs	SEK 698.00k	Veri yok
Andreas Eggert	Independent Director	5.7yrs	SEK 578.00k	0.010% SEK 180.4k
Gunnar Tufveson	Chairman of European Medical Advisory Board in Transplantation	no data	Veri yok	Veri yok
Kathryn Wood	Member - European Medical Advisory Board-Transplantation & US Medical Advisory Board-Transplantation	no data	Veri yok	Veri yok
Christophe Legendre	Member of European Medical Advisory Board in Transplantation	no data	Veri yok	Veri yok
Stanley Jordan	Chairman of US Medical Advisory Board in Transplantation	no data	Veri yok	Veri yok
Robert Montgomery	Member of US Medical Advisory Board in Transplantation	no data	Veri yok	Veri yok

4.7yrs

Ortalama Görev Süresi

58.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: HNSAS 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 4.7 yıldır).

Hansa Biopharma Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Matthew Shaulis, Chief Commercial Officer and US President Decides to Leave Hansa Biopharma AB in Late September

Hansa Biopharma AB (publ) Announces Board Appointments

Hansa Biopharma AB (Publ) Announces CFO Changes

Hansa Biopharma AB (publ), Annual General Meeting, Jun 27, 2024

Hansa Biopharma Nomination Committee Formed

Hahansa Biopharma AB (Publ) Announces Resignation of Donato Spota as Chief Financial Officer, Effective 28 February 2024

Recent updates

Hansa Biopharma AB (publ) to Report Fiscal Year 2024 Final Results on Mar 21, 2025

Hansa Biopharma's Hnsa-5487 Achieves Rapid and Highly Robust Igg Reduction by More Than 95% and Clear Redosing Potential in First-In-Human Trial

Hansa Biopharma AB (publ) to Report Nine Months, 2025 Results on Oct 23, 2025

Matthew Shaulis, Chief Commercial Officer and US President Decides to Leave Hansa Biopharma AB in Late September

Hansa Biopharma AB (publ) to Report Q1, 2025 Results on Apr 17, 2025

Hansa Biopharma AB (publ) Announces Board Appointments

Hansa Biopharma Completes Randomization in Pivotal Phase 3 Us Confides Trial

Hansa Biopharma AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 372.1536 million.

Hansa Biopharma AB (Publ) Announces CFO Changes

Hansa Biopharma AB (publ) to Report Nine Months, 2024 Results on Oct 24, 2024

Hansa Biopharma AB (publ), Annual General Meeting, Jun 27, 2024

Hansa Biopharma AB (Publ) Provides Earnings Guidance for the Fourth Quarter and Full Year 2023

Hansa Biopharma Announces Full Results from 16-HMedIdeS-12 Phase 2 Trial in Patients with Antibody Mediated Rejection Episodes Following Kidney Transplantation

Hansa Biopharma Nomination Committee Formed

Hansa Biopharma Announces Positive High-Level Data from the 15-HMedIdeS-09 Phase 2 Trial

Hahansa Biopharma AB (Publ) Announces Resignation of Donato Spota as Chief Financial Officer, Effective 28 February 2024

Hahansa Biopharma AB (Publ) Announces Resignation of Donato Spota as Chief Financial Officer, Effective 28 February 2024

Hahansa Biopharma AB (Publ) Announces Resignation of Donato Spota as Chief Financial Officer, Effective 28 February 2024

Hansa Biopharma Provides Update on ConfIdeS Phase 3 Trial of Imlifidase in Highly Sensitized Kidney Transplant Patients

Hansa Biopharma Announces Encouraging High-Level Results for First-In-Human Trial of HNSA-5487

Hitto Kaufmann Appointed Chief Scientific Officer of Hansa Biopharma, Effective 1 December 2023

Hitto Kaufmann Appointed Chief Scientific Officer of Hansa Biopharma

Hansa Biopharma AB (publ) to Report Q1, 2024 Results on Apr 17, 2024

Hansa Biopharma Announces First Patient Treated with Imlifidase in an Investigator-Initiated Phase 2 Study in Anca-Associated Vasculitis

Hansa Biopharma Receives Provisionally Approval in Australia as Desensitization Treatment in Highly Sensitized Patients Prior to Kidney Transplantation

Hansa Biopharma Announces First Patient Dosed with Imlifidase in a Global Pivotal Phase 3 Trial in Anti-Inaugular Basement Membrane (anti-GBM) Disease

First quarter 2023 earnings released

Hansa Biopharma Announces Planned Departure of Chief Scientific Officer Christian Kjellman

Hansa Biopharma Announces Positive Reimbursement Decision for Idefirix[®] (Imlifidase) in the Czech Republic

Hansa Biopharma Announces Positive Reimbursement Decision for Idefirix[®] (Imlifidase) in the Czech Republic

Hansa Biopharma AB (publ) Announces Formation of Nomination Committee

Hansa Biopharma AB (publ) has completed a Follow-on Equity Offering.

Hansa Biopharma AB (Publ) Announces Positive Reimbursement Decision in Italy for Idefirix (Imlifidase) as Desensitization Treatment for Highly Sensitized Patients in Kidney Transplantation

Hansa Biopharma AB Announces Positive Topline Data from the Imlifidase Phase 2 Study in Antibody Mediated Rejection (AMR) Episodes Post Kidney Transplantation

Hansa Biopharma AB and Partner Sarepta Therapeutics Plan to Initiate A Clinical Study with Imlifidase as A Pre-Treatment to Sarepta's SRP-9001 Gene Therapy in DMD in 2023

Hansa Biopharma AB (publ) to Report First Half, 2023 Results on Jul 20, 2023

The Scottish Medicines Consortium Recommends Use of Hansa Biopharma's Idefirix[®] (Imlifidase) as Desensitization Treatment for Highly Sensitized Kidney Transplant Patients

Hansa Biopharma AB and Medison Pharma Announce Positive Reimbursement Decision in Poland for Idefirix in Highly Sensitized Kidney Transplant Patients

Second quarter 2022 earnings released: kr3.82 loss per share (vs kr2.98 loss in 2Q 2021)

Hansa Biopharma AB (publ) announced that it has received $70 million in funding from NovaQuest Capital Management, L.L.C.

Hansa Biopharma Announces First Patient Treated in the Post-Authorization Efficacy Study (PAES) of Idefirix® (Imlifidase) in Highly Sensitized Kidney Transplant Patients

Hansa Biopharma AB (publ) Appoints Peter Nicklin as A New Member of the Board of Director

NICE Recommends Use of Hansa Biopharma's Idefirix (Imlifidase) as Desensitization Treatment for Highly Sensitized Kidney Transplant Patients

Hansa Biopharma AB (publ) Announces Ulf Wiinberg Not to Stand for Re-Election as Director

Hansa Biopharma Completes Enrollment in Imlifidase Phase 2 Study in Antibody Mediated Rejection (AMR) Episodes Post Kidney Transplantation

Hansa Biopharma Announces Temporary Marketing Authorization in Switzerland for Idefirix (Imlifidase) in Kidney Transplantation

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş